

Valentina Sala

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3488604/publications.pdf>

Version: 2024-02-01

29
papers

1,135
citations

567281

15
h-index

454955

30
g-index

31
all docs

31
docs citations

31
times ranked

2667
citing authors

#	ARTICLE	IF	CITATIONS
1	High Levels of Cre Expression in Neuronal Progenitors Cause Defects in Brain Development Leading to Microencephaly and Hydrocephaly. <i>Journal of Neuroscience</i> , 2006, 26, 9593-9602.	3.6	152
2	Phosphoinositide 3-Kinase Gamma Inhibition Protects From Anthracycline Cardiotoxicity and Reduces Tumor Growth. <i>Circulation</i> , 2018, 138, 696-711.	1.6	145
3	Cellular and molecular mechanisms of HGF/Met in the cardiovascular system. <i>Clinical Science</i> , 2015, 129, 1173-1193.	4.3	112
4	Inhalation of the prodrug PI3K inhibitor CL27c improves lung function in asthma and fibrosis. <i>Nature Communications</i> , 2018, 9, 5232.	12.8	86
5	The novel butyrate derivative phenylalanine- ϵ -butyramide protects from doxorubicin-induced cardiotoxicity. <i>European Journal of Heart Failure</i> , 2019, 21, 519-528.	7.1	80
6	Understanding the common mechanisms of heart and skeletal muscle wasting in cancer cachexia. <i>Oncogenesis</i> , 2021, 10, 1.	4.9	75
7	Preventing and Treating Anthracycline Cardiotoxicity: New Insights. <i>Annual Review of Pharmacology and Toxicology</i> , 2021, 61, 309-332.	9.4	74
8	Agonist antibodies activating the Met receptor protect cardiomyoblasts from cobalt chloride-induced apoptosis and autophagy. <i>Cell Death and Disease</i> , 2014, 5, e1185-e1185.	6.3	61
9	Novel therapy for myocardial infarction: can HGF/Met be beneficial?. <i>Cellular and Molecular Life Sciences</i> , 2011, 68, 1703-1717.	5.4	42
10	Signaling to Cardiac Hypertrophy: Insights from Human and Mouse RASopathies. <i>Molecular Medicine</i> , 2012, 18, 938-947.	4.4	39
11	Signaling Pathways Underlying Anthracycline Cardiotoxicity. <i>Antioxidants and Redox Signaling</i> , 2020, 32, 1098-1114.	5.4	36
12	MicroRNAs in myocardial ischemia: identifying new targets and tools for treating heart disease. New frontiers for miR-medicine. <i>Cellular and Molecular Life Sciences</i> , 2014, 71, 1439-1452.	5.4	34
13	HGF/Met Axis in Heart Function and Cardioprotection. <i>Biomedicines</i> , 2014, 2, 247-262.	3.2	32
14	PI3K Signaling in Tissue Hyper-Proliferation: From Overgrowth Syndromes to Kidney Cysts. <i>Cancers</i> , 2017, 9, 30.	3.7	29
15	Digoxin and ouabain induce the efflux of cholesterol via liver X receptor signalling and the synthesis of ATP in cardiomyocytes. <i>Biochemical Journal</i> , 2012, 447, 301-311.	3.7	27
16	Activated Met Signalling in the Developing Mouse Heart Leads to Cardiac Disease. <i>PLoS ONE</i> , 2011, 6, e14675.	2.5	15
17	Gene expression profiling of HGF/Met activation in neonatal mouse heart. <i>Transgenic Research</i> , 2013, 22, 579-593.	2.4	12
18	Cardiac concentric hypertrophy promoted by activated Met receptor is mitigated in vivo by inhibition of Erk1,2 signalling with Pimasertib. <i>Journal of Molecular and Cellular Cardiology</i> , 2016, 93, 84-97.	1.9	12

#	ARTICLE	IF	CITATIONS
19	A New Transgenic Mouse Model of Heart Failure and Cardiac Cachexia Raised by Sustained Activation of Met Tyrosine Kinase in the Heart. <i>BioMed Research International</i> , 2016, 2016, 1-13.	1.9	10
20	Inhaled Biologicals for the Treatment of Cystic Fibrosis. <i>Recent Patents on Inflammation and Allergy Drug Discovery</i> , 2019, 13, 19-26.	3.6	9
21	Roles of phosphatidylinositol 3 kinase gamma (PI3K γ) in respiratory diseases. <i>Cell Stress</i> , 2021, 5, 40-51.	3.2	9
22	A mouse model for spatial and temporal expression of HGF in the heart. <i>Transgenic Research</i> , 2011, 20, 1203-1216.	2.4	8
23	Therapeutic peptides for the treatment of cystic fibrosis: Challenges and perspectives. <i>European Journal of Medicinal Chemistry</i> , 2021, 213, 113191.	5.5	8
24	A PI3K γ mimetic peptide triggers CFTR gating, bronchodilation, and reduced inflammation in obstructive airway diseases. <i>Science Translational Medicine</i> , 2022, 14, eabl6328.	12.4	6
25	Therapeutic Targeting of PDEs and PI3K in Heart Failure with Preserved Ejection Fraction (HFpEF). <i>Current Heart Failure Reports</i> , 2017, 14, 187-196.	3.3	5
26	Hepatocyte Growth Factor-mediated satellite cells niche perturbation promotes development of distinct sarcoma subtypes. <i>ELife</i> , 2016, 5, .	6.0	5
27	New avenues in cardio-oncology. <i>Aging</i> , 2019, 11, 1075-1076.	3.1	4
28	The Role of Anthracyclines in Cardio-Oncology: Oxidative Stress, Inflammation, and Autophagy. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-3.	4.0	4
29	Anti-Differentiation Effect of Oncogenic Met Receptor in Terminally-Differentiated Myotubes. <i>Biomedicines</i> , 2015, 3, 124-137.	3.2	3